Core Viewpoint - A class action lawsuit has been filed against Elevance Health, Inc. for allegedly failing to disclose the impact of Medicaid redetermination on its business prospects, leading to significant financial misrepresentation [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Elevance Health misled investors by stating that they were monitoring Medicaid cost trends and that premium rates were sufficient to manage risks, despite rising Medicaid expenses [2]. - The company allegedly failed to disclose that the Medicaid redetermination process was resulting in a higher acuity and utilization of its Medicaid members, which was not reflected in their financial guidance for 2024 [2]. - Following the revelation of increased utilization expectations in the Medicaid sector, Elevance's stock price dropped by $32.21 per share, or 5.8%, indicating a significant market reaction to the disclosed information [3]. Group 2: Legal Proceedings - Shareholders interested in participating in the class action must file their papers by July 11, 2025, to serve as lead plaintiff, representing the interests of other class members [4]. - Shareholders are not required to participate in the case to be eligible for recovery, allowing them to remain absent class members if they choose [4]. Group 3: Company Background - Robbins LLP, the law firm handling the case, has been focused on shareholder rights litigation since 2002, aiming to help shareholders recover losses and improve corporate governance [5].
ELV Class Action Lawsuit – Shareholders Should Contact Robbins LLP for Information About Leading the Class Action Against Elevance Health, Inc.